Established in Hong Kong on March 19, 2019, Pulmongene Ltd. is a company dedicated to the innovation and development of novel pharmaceuticals targeting respiratory illnesses and organ fibrosis treatments.
[Translation] A Phase 1b, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, and pharmacokinetics of multiple-dose, dose-escalating PMG1015 injection in subjects with idiopathic pulmonary fibrosis (IPF)
评估PMG1015注射液在IPF受试者中多次给药及剂量递增的安全性和耐受性。
[Translation]
To evaluate the safety and tolerability of multiple dosing and dose escalation of PMG1015 injection in IPF subjects.
A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PMG1015 in Idiopathic Pulmonary Fibrosis (IPF) Subjects
This is a phase 1b randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study of PMG1015 in idiopathic pulmonary fibrosis (IPF) subjects. This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after MAD.
[Translation] A randomized, double-blind, placebo-controlled, single-ascending dose Phase Ia study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of PMG1015 injection in healthy volunteers
评估PMG1015注射液在健康志愿者中的安全性、耐受性、药代动力学和免疫原性。
[Translation]
To evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of PMG1015 injection in healthy volunteers.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.